Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Abstract Background Whereas there are many pharmacological interventions prescribed for patients with advanced anaplastic lymphoma kinase (ALK)- rearranged non-small cell lung cancer (NSCLC), comparative data between novel generation ALK-tyrosine kinase inhibitors (TKIs) remain scant. Here, we indir...

Full description

Bibliographic Details
Main Authors: Hao-chuan Ma, Yi-hong Liu, Kai-lin Ding, Yu-feng Liu, Wen-jie Zhao, Yan-juan Zhu, Xue-song Chang, Ya-dong Chen, Zhen-zhen Xiao, Ya-ya Yu, Rui Zhou, Hai-bo Zhang
Format: Article
Language:English
Published: BMC 2021-11-01
Series:BMC Cancer
Subjects:
ALK
Lung cancer
First-line treatment
Network meta-analysis
Online Access:https://doi.org/10.1186/s12885-021-08977-0

Internet

https://doi.org/10.1186/s12885-021-08977-0

Similar Items